Smith, Gale

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,156

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Tian, J.-H., Patel, N., Haupt, R., Zhou, H., Weston, S., Hammond, H., Logue, J., Portnoff, A. D., Norton, J., Guebre-Xabier, M., et al. (2021) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 508

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., et al. (2021) · Cell Host & Microbe

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 378

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Guebre-Xabier, M., Patel, N., Tian, J.-H., Zhou, B., Maciejewski, S., Lam, K., Portnoff, A. D., Massare, M. J., Frieman, M. B., Piedra, P. A., et al. (2020) · Vaccine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 231

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Shen, X., Tang, H., Pajon, R., Smith, G., Glenn, G. M., Shi, W., Korber, B., & Montefiori, D. C. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 193

Intranasal Vaccination with 1918 Influenza Virus-Like Particles Protects Mice and Ferrets from Lethal 1918 and H5N1 Influenza Virus Challenge

Perrone, L. A., Ahmad, A., Veguilla, V., Lu, X., Smith, G., Katz, J. M., Pushko, P., & Tumpey, T. M. (2009) · Journal of Virology

Influenza Virus Research StudiesVirology and Viral Diseases

Cited by 143

Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin–Matrix-M® nanoparticle vaccine induces neutralizing responses in nonhuman primates

Patel, N., Rehman, A., Trost, J. F., Flores, R., Longacre, Z., Guebre-Xabier, M., Zhou, H., Zhou, B., Jacobson, K., Jiang, D., et al. (2025) · Nature Communications

Influenza Virus Research StudiesVirology and Viral Diseases

Cited by 6

Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin–Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates

Patel, N., Rehman, A., Trost, J. F., Flores, R., Longacre, Z., Guebre-Xabier, M., Zhou, H., Zhou, B., Jacobson, K., Jiang, D., et al. (2024) · Nature Communications

Influenza Virus Research StudiesVirology and Viral Diseases

Cited by 6